We partner with BioMed Central's open access journal, Molecular Neurodegeneration (MN), which is the official journal of BrightFocus. The open access publishing model provides free articles to the general public, as well as scientists, clinicians, and other healthcare practitioners.
MN publishes peer-reviewed, original scientific research on the causes of neurodegenerative diseases, such as Alzheimer's or Parkinson' and on the pre-clinical testing of potential therapies for these devastating diseases.
MN has an impact score of 8.274 (with a 5-year impact factor of 8.102, reflecting the sustained impact of our journal) and remains the highest ranked open access neuroscience journal in the Journal Citation Reports (JCR).
Better Understanding of Tau Immunotherapies For Alzheimer’s Disease
Learn about a promising approach for targeting one of the hallmarks of Alzheimer’s disease, abnormal forms of the tau protein, using immunotherapy, in which antibodies are used to bind to the pathological protein and promote its clearance.